10 August 2018

Andera Partners co-leads $84 million (£65 million) Series B Financing in Artios Pharma

With its investment into Artios Pharma, Andera Partners continues on its track to back highly experienced management teams translating outstanding science into innovative treatment modalities.

 

Paris, France, 10 August 2018. Andera Partners, a leading Venture Capital Life Sciences Investor,  today announced the co-lead of a $86 million (£65 million) Series B financing of Artios Pharma Limited (Artios), a DNA Damage Response (DDR) company developing innovative treatments for cancer.  The financing, which was significantly oversubscribed, was led by Andera Partners (formerly EdRIP) and LSP (Life Sciences Partners), with participation by additional new investors Pfizer Ventures and Novartis Venture Fund (NVF). Artios’ existing shareholders Arix Bioscience, SV Health Investors, M Ventures, IP Group plc and AbbVie Ventures also participated in the fundraise. 

 

 

“We believe Artios’ DDR programmes have the potential to bring real impact to cancer patients. DDR is an exciting field of biology, which has been clinically validated by the first generation PARP inhibitors currently on the market. The new funds will allow Artios to advance its portfolio of first-in-class, small molecule DDR programmes including its lead programme targeting DNA polymerase theta (Polθ), through clinical proof of concept trials. We are delighted to work with the management team in building a world class DDR targeted oncology company.”

Raphael Wisniewski

Partner of Andera Partners

“We are delighted to welcome Andera Partners, LSP, Pfizer Ventures and Novartis Venture Fund to Artios and I would like to thank our existing investors for their continued support, which will help us develop and deliver our exciting DDR targeted therapies to cancer patients. This investor syndicate creates a very strong and committed shareholder base with a track record of supporting successful next generation companies. The oversubscribed Series B fundraise is a strong endorsement of our world-leading development pipeline and reflects the opportunity for DDR to yield new breakthrough oncology products.”

Niall Martin

Chief Executive Officer of Artios

Artios is actively developing a pipeline of highly promising first-in-class DDR therapies identified from a global network of leading researchers in the DDR field, including through Cancer Research UK. The inhibition of novel DNA repair targets like Polθ, in tumours where DNA damage response factors have been lost or down regulated, will lead to cancer cells being selectively killed without harming normal cells. This creates an opportunity for such products to be used both in monotherapy and in combination with existing and future cancer therapies.

 

In conjunction with the Series B financing, Raphael Wisniewski from Andera Partners will join the Board of Artios as a director. This financing follows a $36 million Series A fundraise that was completed in September 2016.

 

END

 

For more information about Andera Partners or inquiries on this transaction, please contact:

 

Consilium Strategic Communications

Amber Fennell, Melissa Gardiner, Lindsey Neville

Andera@consilium-comms.com

+44 (0) 20 3709 5700

 

About Andera Partners

Andera Partners is a leading investor in minority investments into privately owned companies. Previously Edmond de Rothschild Investment Partners, the Management Company employs 56 people and has more than €2 billion under management. Its Life Sciences team of 11 professionals brings together deep experience both in the Life Science industry and in private equity and venture capital. The team has raised more than €800 million through its BioDiscovery franchise and is currently investing out of its € 345 million BioDiscovery 5 fund. Since their inception, BioDiscovery Funds have invested in some 60 privately held companies, of which 16 have been sold and 16 listed on public financial markets, while more than 20 are active in the portfolios.

For more information, please visit www.anderapartners.com.

 

About Artios Pharma Limited

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as the National Centre for Biomolecular Research at Masaryk University. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. Backed by blue chip investors including: Arix Bioscience plc - Artios’ largest shareholder, SV Health Investors, M Ventures, IP Group plc, AbbVie Ventures, Andera Partners (formerly EdRIP), LSP (Life Science Partners), Pfizer Ventures and Novartis Venture Fund (NVF). Artios is based at the Babraham Research Campus in Cambridge, UK. www.artiospharma.com

 

 

 


Back to previous page